UK Central Nervous System Therapeutic Market Size & Outlook
Related Markets
UK central nervous system therapeutic market highlights
- The UK central nervous system therapeutic market generated a revenue of USD 5,020.4 million in 2024 and is expected to reach USD 7,850.5 million by 2030.
- The UK market is expected to grow at a CAGR of 8% from 2025 to 2030.
- In terms of segment, mental health was the largest revenue generating disease in 2024.
- Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
Central nervous system therapeutic market data book summary
| Market revenue in 2024 | USD 5,020.4 million |
| Market revenue in 2030 | USD 7,850.5 million |
| Growth rate | 8% (CAGR from 2025 to 2030) |
| Largest segment | Mental health |
| Fastest growing segment | Neurodegenerative Diseases |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
| Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
Other key industry trends
- In terms of revenue, UK accounted for 3.9% of the global central nervous system therapeutic market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany central nervous system therapeutic market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 4,912.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Central Nervous System Therapeutic Market Scope
Central Nervous System Therapeutic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
UK central nervous system therapeutic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 36.33% in 2024. Horizon Databook has segmented the UK central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The rising prevalence of mental illnesses and increasing expenditure on mental health care by the UK government are the primary drivers of the UK CNS therapeutics market. Moreover, according to the Office for National Statistics, UK, dementia and Alzheimer’s disease are the leading causes of deaths in the country.
The main drugs used in the treatment of Alzheimer’s here are NMDA receptor antagonists and acetylcholinesterase inhibitors. Cholinesterase inhibitors are generically known as galantamine, donepezil, and rivastigmine, while NMDA receptor.
Parkinson’s disease is also expected to increase at a rapid pace over the forecast period, mainly due to aging population. For instance, the Parkinson’s disease Society of the United Kingdom reported that the prevalence of Parkinson’s disease in the UK .
Reasons to subscribe to UK central nervous system therapeutic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK central nervous system therapeutic market databook
-
Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into UK central nervous system therapeutic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK Neurodegenerative Diseases - Central Nervous System Therapeutic Market, 2024 - 2030 (US$M)
UK Central Nervous System Therapeutic Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
